Therapeutic response to taxol of six human tumors xenografted into nude mice

To test the antineoplastic activity of taxol, a natural product isolated from yew (Taxus baccata L.), six human tumors transplanted into athymic mice were used (primary tumors of breast, endometrium, ovary, brain, lung and a recurrence of tongue tumor). While the growth rates varied with the histopa...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1986-06, Vol.17 (2), p.137-142
Main Authors: RIONDEL, J, JACROT, M, PICOT, F, BERIEL, H, MOURIQUAND, C, POTIER, P
Format: Article
Language:English
Subjects:
Adult
Aged
Alkaloids - therapeutic use
Alkaloids - toxicity
Animals
Antineoplastic Agents
Biological and medical sciences
Chemotherapy
Female
Humans
Male
Medical sciences
Mice
Mice, Nude
Middle Aged
Neoplasm Transplantation
Neoplasms, Experimental - drug therapy
Paclitaxel
Pharmacology. Drug treatments
Rats
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To test the antineoplastic activity of taxol, a natural product isolated from yew (Taxus baccata L.), six human tumors transplanted into athymic mice were used (primary tumors of breast, endometrium, ovary, brain, lung and a recurrence of tongue tumor). While the growth rates varied with the histopathological characteristics of different tumor types, all mice were treated at a mean tumor volume of 200 +/- 8 mm3. Taxol was given SC at a dose level of 12.5 mg/kg per injection per day for 5 consecutive days out of 7 over a period of 3 weeks. With this schedule antitumor responses were obtained in all of the six neoplasms xenografted into nude mice. In the case of the ductal carcinoma of the breast total tumor regressions were observed in four of the five treated animals. In the five other experimental models taxol produced significant growth delays. We believe that the results of these initial tests on the nude mouse--human tumor xenograft system are convincing and justify clinical assessment of this drug.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00306742